IP Library Granted Patent US 10,583,187
Granted Patent B2
US 10,583,187 · App. 15/946,664 · Granted Mar 10, 2020

Glycoconjugation processes and compositions

Inventors: Jianxin Gu (River Edge, NJ); Jin-hwan Kim (Suffern, NY); Avvari Krishna Prasad (Chapel Hill, NC); Yu-ying Yang (Stamford, CT)
Assignee: Pfizer Inc.
A61K39/095A61K39/092A61K45/06A61K47/64A61K47/646A61K47/6415A61K2039/6037A61K2039/6068A61K2039/627
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,187
App. No.
15/946,664
Granted
Mar 10, 2020
Kind
B2
Abstract

The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Claims (10)

1. A glyconconjugate comprising a Streptococcus pneumoniae -derived capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein said glyconconjugate comprises less than about 15% free saccharide.

2. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 33F capsular polysaccharide.

3. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 22F capsular polysaccharide.

4. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 10A capsular polysaccharide.

5. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 11A capsular polysaccharide.

6. An immunogenic composition comprising a glycoconjugate according to claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent.

7. An immunogenic composition according to claim 6 further comprising an additional antigen.

8. An immunogenic composition according to claim 7 , wherein the additional antigen comprises a glycoconjugate of a Streptococcus pneumoniae -derived capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 22F, 23F and 33F capsular polysaccharides.

9. An immunogenic composition according to claim 8 further comprising at least one adjuvant.

10. An immunogenic composition according to claim 1 , wherein said carrier protein is CRM 197 .

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (4)
Continuation 15347034 · Nov 9, 2016
Continuation 14420822
Provisional Application 61684043 · Aug 16, 2012
Related Publication 20180221467A1 · Aug 9, 2018
Cited By (3)
US 12,251,438 US 12,343,389 US 12,447,203